Timothy J. Soos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Timothy J. Soos has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Fanelli
Target and Systems Immunology Institute, TSU/Immuno Inflammation, Sanofi, Bridgewater, NJ, USA
1 shared publication - Christopher W. Arendt
Bio-Innovation Group of Sanofi Biotherapeutics, 38 Sidney Street, Sanofi, Cambridge, MA, 02142, USA
1 shared publication Daniel Weinstock
13Immunotoxicology and Experimental Pathology, Biologics Toxicology, Biologics Center of Excellence Janssen Research and Development, LLC, Springhouse, PA, USA
1 shared publication- Deborah Iglesias-Bregna
Electrophysiology-Pharmaco EEG, Bioanalysis/Physiology, Lundbeck Research USA, Inc., Paramus, NJ, USA
1 shared publication - Donghui Zhang
Translational and Early Development Biostatistics, Sanofi, 200 West St., Waltham, MA 02451, USA
1 shared publication - Garth E. Ringheim
Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ 07901
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 169
Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis
Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing forms of multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 169
Open AccessTeriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis
Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing forms of multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.